Gabriela (Gaby) Morales-Rivera is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals, and medical devices. Gaby represents public and private companies in startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, strategic investments, and other complex transactions.
She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Gaby has worked with many of her company-side clients since their initial founding and funding.
Experience
- Nimbus Therapeutics in connection with its $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences, its financings of more than $290 million, and its $6 billion sale of its TYK2 inhibitor to Takeda Pharmaceuticals
- ElevateBio, LLC in connection with its $150 million Series A financing, $193 million Series B financing, $525 million Series C financing, its $401 million Series D financing and the formation of its portfolio companies
- ReNAgade Therapeutics, LLC in connection with its formation, its $300 million Series A financing and its joint venture with Orna Therapeutics
- Bicara Therapeutics in its $108 million Series B financing
- MoMa Therapeutics in its formation, $86 million Series A financing and $150 million Series B financing
- ROME Therapeutics with its formation, $50 million Series A financing and $77 million Series B financing
- Forma Therapeutics in connection with its $100 million Series D financing, its $319.3 million initial public offering, its $275.8 million follow-on public offering, its $200 million “at-the-market” offering, and its $1.1 billion sale to Novo Nordisk
- Aptinyx in connection with its $65 million Series A financing, its $70 million Series B financing, and its $117.8 million initial public offering
- Kymera Therapeutics in connection with its $30 million Series A financing, its $65 million Series B financing, its research and development collaboration with Vertex Pharmaceuticals, and its $200 million initial public offering
- Exosome Diagnostics in connection with its $30 million Series C financing and its sale to Bio-Techne Corporation
- Tango Therapeutics in connection with its formation, $55 million Series A financing and its $60 million Series B financing
- Cullinan Oncology in its $98.5 million Series B Financing, its $131.2 million Series C Financing, its $287.4 million initial public offering and the formation of its portfolio companies
- Intellia Therapeutics in connection with day to day governance and reporting matters, its multiple follow-on offerings of more than $1.0 billion, its “at-the-market” offerings, its expanded licensing agreement with Regeneron Pharmaceuticals, its collaboration and spin-out transaction with Blackstone Life Sciences, and its acquisition of Rewrite Therapeutics
- Akero Therapeutics in connection with its formation, $65 million Series A financing, its $70 million Series B financing, its $105.8 million initial public offering, multiple follow-on offerings of more than $425 million, a $25 million equity investment by Pfizer, Inc. its $100 million term loan facility with Hercules Capital, Inc. and day-to-day governance and reporting matters.
- Relay Therapeutics in connection with its formation, $57 million Series A financing, its $63 million Series B financing and its $400 million Series C financing, its $460 million initial public offering, and multiple follow-on offerings of more than $300 million, its $85 million acquisition of ZebiAI, and day-to-day governance and reporting matters.
- Cabaletta Bio in connection with day-to-day governance and reporting matters, its $75 million “at-the-market” offering and its follow-on offering and sale of pre-funded warrants for an aggregate of $35 million
- Vigil Neuroscience in connection with day-to-day governance and reporting matters, its $91.1 million initial public offering, its $75.0 million private placement financing, and its “at-the-market” offering
- Adicet Bio, Inc. (formerly resTORbio, Inc.) in connection with day-to-day governance and reporting matters, its $97.8 million initial public offering, the merger between Adicet Bio and resTORbio, its “at-the-market” programs, and multiple follow-on offerings of more than $300 million
- Talaris Therapeutics in connection with day-to-day governance and reporting matters, its $150 million initial public offering and its “at-the-market” program
- Neon Therapeutics in connection with its $106 million Series B financing, its $100 million initial public offering, and its $97 million sale to BioNTech
- Sage Therapeutics in its follow-on offerings of more than $800 million
- Repligen Corp. in connection with its acquisition of TangenX Technology Corporation, its acquisition of Spectrum, Inc. and its $138 million follow-on offering
Professional Activities
While attending law school, Gaby interned for the Honorable Juan R. Torruella of the First Circuit Court of Appeals.
Gaby is a member of the Boston and American Bar Associations as well as the Hispanic National Bar Association.
Credentials
Education
JD2015
Boston University School of Law
BA2012
Swarthmore College
Admissions
Bars
- Massachusetts
Recognition & Awards
Gaby has been recognized by The Best Lawyers in America Ones to Watch for her work in Corporate and Technology Law and Life Sciences Practice 2022 and 2023. Gaby was also shortlisted for LMG Life Sciences’ Americas 2023 US Rising Star – Financial & Corporate Award.